University of Pennsylvania to Join First-of-its-Kind Research Collaboration to Fight Cancer with New Immunotherapies
The University of Pennsylvania has joined an unprecedented cancer research effort, the Parker Institute for Cancer Immunotherapy, which unites six of the nation's top medical schools and cancer centers around a shared aim of accelerating breakthrough immunotherapy research that will turn more cancers into a curable disease.
High Response Rates, Long-Term Remissions Seen In Penn Trials of Personalized Cellular Therapy CTL019 for Pediatric and Adult Blood Cancers
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over one year in 18 patients and over two years in nine patients.
Penn Researchers Report Sustained Remission After Treatment with Investigational Personalized Cellular Therapy In Patient with Multiple Myeloma
A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
Abramson Cancer Center Researchers Report Long-Term Remissions in First Group of Patients to Receive Personalized Cellular Therapy for Chronic Lymphocytic Leukemia
Eight of 14 patients in the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four and a half years.
Abramson Cancer Center Researchers Report Results from Newest Trials of Personalized Cellular Therapies for Three Cancers
The latest results of clinical trials utilizing a personalized cellular therapy developed by a team from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania will be presented today during the annual meeting of the American Society of Clinical Oncology in Chicago's McCormick Place.
Penn Medicine Researchers Receive 7.5 Million Dollars to Expand HIV Gene Therapy Work
Researchers from the Perelman School of Medicine and the Penn Center for AIDS Research (CFAR) have been awarded 7.5 million dollars over five years from the National Institutes of Health to initiate a multi-project HIV study investigating a new gene therapy approach to render immune cells of HIV positive patients resistant to the virus.
University of Pennsylvania Team Receive Prestigious National Clinical Research Award for HIV Breakthrough
Researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Center for AIDS Research (CFAR) are among the 2015 recipients of the prestigious Clinical Research Achievement Award for their personalized gene therapy work in HIV.
Penn Medicine Study Describes Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. The results paved the way for a newly opened clinical trial for glioblastoma patients at Penn.
Research Study of Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied
Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. The results are published this week in The New England Journal of Medicine.
Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus
The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.
University of Pennsylvania's Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this important classification.
Penn Medicine Team Reports Findings from Research Study of First 59 Adult and Pediatric Leukemia Patients Who Received Investigational, Personalized Cellular Therapy CTL019
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies.
Personalized Gene Therapy Locks Out HIV, Paving the Way to Control Virus Without Antiretroviral Drugs
University of Pennsylvania researchers have successfully genetically engineered the immune cells of 12 HIV positive patients to resist infection, and decreased the viral loads of some patients taken off antiretroviral drug therapy (ADT) entirely—including one patient whose levels became undetectable.
Genetically Modified "Serial Killer" T Cells Obliterate Tumors in Patients with Chronic Lymphocytic Leukemia, Penn Researchers Report
In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.